SEC Comment Letter for INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519) — Mar 2, 2020
INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)
Date: March 2, 2020 · CIK: 0001292519 · Accession: 0000000000-20-001888
AI Filing Summary & Sentiment
File numbers found in text: 001-37350
Letter
March 2, 2020 Richard Toselli, M.D. Chief Executive Officer InVivo Therapeutics Holdings Corp. One Kendall Square, Suite B14402 Cambridge, MA 02139 Re:InVivo Therapeutics Holdings Corp. Preliminary Proxy Statement on Schedule 14A Filed November 8, 2019 File No. 001-37350 Dear Dr. Toselli: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rosemary G. Reilly, Esq.
Show Raw Text
March 2, 2020
Richard Toselli, M.D.
Chief Executive Officer
InVivo Therapeutics Holdings Corp.
One Kendall Square, Suite B14402
Cambridge, MA 02139
Re:InVivo Therapeutics Holdings Corp.
Preliminary Proxy Statement on Schedule 14A
Filed November 8, 2019
File No. 001-37350
Dear Dr. Toselli:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Rosemary G. Reilly, Esq.